Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Meridian Growth Fund ArrowMark Colorado Holdings, LLC | “Tandem Diabetes Care, Inc. (TNDM) is a medical device company focused on insulin delivery, best known for its t:slim X2 and Mobi automated insulin pumps. We own it for its differentiated pump technology, growing installed base, and the recurring supply revenue that expands with its user base. Shares declined during the quarter as the company's transition to a pharmacy-based, pay-as-you-go reimbursement model clouded near-term revenue visibility, and second-quarter guidance came in below expectations even as the underlying quarter was broadly in line. Heightened attention to a new competing patch-pump entrant added to the caution, and the name's lower-beta profile lagged in a market that favored higher-beta and non-earning stocks; we continue to believe the reimbursement transition is a long-term positive.” | NEUTRAL | Q2 2026 Jul 28, 2026 | View Pitch |
Meridian Small Cap Growth Fund Chad Meade | “Tandem Diabetes Care, Inc. (TNDM) is a medical device company focused on insulin delivery, best known for its t:slim X2 and Mobi automated insulin pumps. We own it for its differentiated pump technology, growing installed base, and the recurring supply revenue that expands with its user base. Shares declined during the quarter as the company's transition to a pharmacy-based, pay-as-you-go reimbursement model clouded near-term revenue visibility, and second-quarter guidance came in below expectations even as the underlying quarter was broadly in line. Heightened attention to a new competing patch-pump entrant added to the caution, and the name's lower-beta profile lagged in a market that favored higher-beta and non-earning stocks; we continue to believe the reimbursement transition is a long-term positive.” | NEUTRAL | Q2 2026 Jul 28, 2026 | View Pitch |
Meridian Growth Fund ArrowMark Colorado Holdings, LLC | “Tandem Diabetes Care, Inc. develops advanced insulin delivery technologies for patients with diabetes. Its automated insulin delivery systems are positioned to gain share in a large and expanding market where many Type 1 diabetes patients still manage insulin manually. The stock appreciated during the quarter, supported by revenue that exceeded expectations and an encouraging growth outlook. Performance was bolstered by a higher proportion of sales through the pharmacy channel, which offers more favorable economics, and several pipeline products nearing commercialization. BSD Analysis: Tandem sells insulin pump systems in a category defined by outcomes and user experience. Its interface-first approach resonates with patients managing daily disease burden. Competition is intense, but switching devices is disruptive and slow. Reimbursement stability underpins demand visibility. Investors focus on growth deceleration and pricing pressure. Yet installed base expansion drives recurring consumables revenue. Pipeline improvements matter more than headline unit sales. This is chronic-care tech where loyalty compounds quietly.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Meridian Small Cap Growth Fund Chad Meade | “Tandem Diabetes Care is an automated insulin delivery technology provider poised for long-term growth in both Type 1 and Type 2 diabetes markets. Although near-term U.S. results were soft due to seasonality and shipping delays, its international performance remains strong. The manager trimmed the position slightly but maintains a constructive view of its large addressable market and market share potential.” | BULL | Q1 2025 Mar 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.